Products & ReviewClinical Diagnostics

BRCA MASTR Dx

A simple, robust and complete CE-IVD validated diagnostic test of breast and ovarian related cancer for detection in MPS The BRCA MASTR™ Dx is a molecular diagnostic assay for the identification of mutations in the coding regions of the BRCA 1&2 genes in individuals with increased risk for breast, ovarian and/or related cancers.Multiplicom’s BRCA MASTR™ Dx is ready to use and offers robust performance with minimum hands-on ti…

Multiplicom N.V

The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our  Product Directory.

Ease of Use
After Sales Service
Value for Money
Write your own review

A simple, robust and complete CE-IVD validated diagnostic test of breast and ovarian related cancer for detection in MPS

The BRCA MASTR™ Dx is a molecular diagnostic assay for the identification of mutations in the coding regions of the BRCA 1&2 genes in individuals with increased risk for breast, ovarian and/or related cancers.

Multiplicom’s BRCA MASTR™ Dx is ready to use and offers robust performance with minimum hands-on time. All reagents necessary to enable multiplex amplification of 93 amplicons (289-430 bp) are included, for complete exon coverage of all coding sequences of the BRCA 1&2 genes. The assay is compatible with all current Massively Parallel Sequencing (MPS) platforms, giving you the flexibility to choose your preferred method.


BRCA MASTR Dx Advantages:

  • Highly efficient workflow - Ready-to-use kit with simple-to-follow protocols for various MPS platforms.
  • Uniform coverage - 99.9% amplicons detected > 0.2X mean coverage.
  • High target specificity - 99.85% on target bases ~30 of intronic flanking sequence.
  • Low amount of DNA required - 20-50 ng per multiplex PCR reaction.

Product Overview

Links